If you are suffering from the deadly sleep disorder called the obstructive sleep apnea (OSA) then you’re not breathing properly while you sleep because your airflow is blocked repeatedly throughout the night.

Almost one in four men and one in ten women suffer from sleep apnea. There are three different types of sleep apnea but obstructive sleep apnea (OSA) is the most common. And it goes hand-in-hand with type 2 diabetes.

Among all of the sleep disorders, OSA has the strongest association with type 2 diabetes. That’s even taking into account other risk factors, such as weight, sex and age.

The main risk factor for OSA is obesity. Excess weight deposits extra fat around the thorax, reducing chest compliance and functional capacity, while increasing oxygen demand. Read the rest of this entry

Lee A. Surkin, MD is the first medical practice in the state of North Carolina to offer Provent Sleep Apnea Therapy, an innovative, non-invasive treatment for obstructive sleep apnea (OSA) to patients in Greenville and throughout North Carolina. Cleared by the US FDA in 2008, Provent Therapy is a simple and effective new treatment option for obstructive sleep apnea. Provent Therapy utilizes the patient’s own breathing to provide clinically proven results in the treatment of OSA.

CPAP (continuous positive airway pressure) is currently the gold standard for treatment of OSA and is extremely effective at treating OSA when worn as directed. However, up to half of all patients are not compliant with CPAP therapy due to the cumbersome nature of the treatment. Provent Therapy was developed to help patients who cannot tolerate CPAP therapy and may benefit from the small non-invasive and effective technology Provent Therapy provides. Read the rest of this entry

Reportlinker.com announces that a new market research report is available in its catalogue:

United States Anesthesia and Respiratory Devices Market Outlook to 2017 – Respiratory Devices, Respiratory Measurement Devices, Airway and Anesthesia Devices, Anesthesia Machines, Sleep Apnea Diagnostic Systems, Pain Management Devices and Others

The report provides key market data on the United States Anesthesia and Respiratory Devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within eight market categories – Airway and Anesthesia Devices, Anesthesia Machines, Pain Management Devices, Regional Anesthesia Disposables, Respiratory Devices, Respiratory Disposables, Respiratory Measurement Devices and Sleep Apnea Diagnostic Systems. Read the rest of this entry

For patients with severe obstructive sleep apnea, three months of continuous positive airway pressure (CPAP) therapy is associated with reduced blood pressure, and partial reversal of metabolic abnormalities, according to a study published in the Dec. 15 issue of the New England Journal of Medicine.

Surendra K. Sharma, M.D., Ph.D., from the All India Institute of Medical Sciences in New Delhi, and colleagues investigated the effects of CPAP treatment on metabolic syndrome in 86 patients with obstructive sleep apnea syndrome. Patients were assigned to real or sham CPAP for three months, followed by a washout period of one month, and then a crossover to the other intervention for three months. Anthropometric variables, blood pressure, fasting blood glucose levels and lipid profile, insulin resistance, glycated hemoglobin levels, carotid intima-media thickness, and visceral fat were measured before and after each intervention. Read the rest of this entry

The Motor Carrier Safety Advisory Committee and  the Medical Review Board of the FMCSA held a joint  public meeting in Alexandria, VA, to discuss guidance for medical examiners  to identify commercial drivers with a high pre-test probability of having  Obstructive Sleep Apnea, define conditional certification, and what constitutes  immediate disqualification. “These recommendations are a step in the right  direction,” commented Richard Thiel, Director of Making Sleep Work For You?, a  nationwide sleep disorder program, “both entities recognize how OSA is an issue  in the industry, and are taking steps to not only address it, but also give  clear guidelines to all stakeholders involved.”

Subcommittees of each group working together will meet in January to draft  more detailed recommendations to the FMCSA, and another joint meeting of these  entities will take place in February 2012 to finalize the detailed  recommendations. A public comment period will also be available before the FMCSA  issues these recommendations as final guidance. Read the rest of this entry

In a shrewd execution of its business plan and growth strategy, Craig Sizer,  Co-founder and Chairman, with Keith Houlihan, Co-founder and President of Sanomedics International Holdings  Inc. announced the signing of a letter of  intent to acquire a strategically targeted durable medical equipment (DME)  provider with a platform in sleep apnea treatment services.  The targeted  acquisition is accredited by the “Healthcare Quality Association.” The operation  with approximately $6 million in revenues and over $1 million in (EBITDA)  earnings before interest, taxes, depreciation and amortization is expected to  close in early 2012 upon the completion of due diligence and Sanomedics board  approval.

“The acquisition of a sleep treatment service based operations is an  important step in the growth of Sanomedics,  as well as for the distribution and sales expansion of our ThermoMedics line of non-contact clinical thermometers,”  said Craig Sizer Chairman and Co-founder. Read the rest of this entry

Gone are the days of an unaffordable oral appliance used to treat the deadly disorder Sleep Apnea.  With over 18 million Americans affected by Obstructive  Sleep Apnea (OSA), it was only a matter of time the market demanded an  affordable and effective oral appliance to treat sleep apnea.  Respire Medical, a Brooklyn based oral  appliance company teamed up with Gergen’s  Orthodontic Lab to provide a significantly less expensive solution to the  worlds Sleep Apnea sufferers.  Dentists can now attend a dental continuing education course  offered by Sleep Group Solutions to learn more the Respire Blue Series and offer an  affordable option.

“As we continue to grow we would like to welcome all of our new clients and  wish them much success in their treatment of OSA with our Respire devices.”   says David Walton, co-creator of the Respire Blue Series.  “Now that we have  been added to the list of Medicare approved devices by the PDAC board, our  Respire Blue Series device is available to more people.”  With a price point  that’s affordable, Respire Medical offers the best value for money across the  market, hands down. Read the rest of this entry

The Snoring Center, the nation’s leading provider of minimally invasive, office-based treatment for snoring and sleep apnea, including the Pillar Procedure from Medtronic, announced the addition of a Gulf Coast center to open January 6.

“We continue to find innovative professionals like Dr. Weiss to join our team and help achieve our mission to change the way people think about snoring and other sleep-related disorders”

Dr. Ray Weiss, a Board Certified Otolaryngologist, will serve as Medical Director of the Snoring Center’s Ocean Spring location, serving patients along the Gulf Coast, from Mobile, Alabama to New Orleans, Louisiana.

“I am proud to be able to bring relief to patients with the support of The Snoring Center,” said Dr. Weiss. “We are working to improve quality  of life for patients all over the world. Continuing to expand The Snoring Center team into new markets allows ease of access for the men and women seeking minimally invasive, office-based snoring and sleep apnea treatment, and I am glad to be a part of it.” Read the rest of this entry

Sleep apnea is a dangerous problem that can lead to heart attacks, strokes, excessive daytime sleepiness, short-term memory loss and increases in motor vehicle accidents. It is essential to diagnose and treat sleep apnea. One study showed a 36% decrease in 8 year survival comparing treated and untreated sleep apnea.

A problem frequently experienced is that the cost of health, life and disability insurance policies can increase exponentially following diagnosis of sleep apnea. This is problematic for owners of small businesses and wealthy individuals who utilize life insurance to protect their estates. Read the rest of this entry

Henry Schein Inc., the largest provider of health care products and services to office-based practitioners, today announced the launch of its Sleep Complete™ program, a new integrated comprehensive solution that provides all of the information and products necessary for the successful implementation of dental sleep medicine into the dental practice. A key component of this package will be Itamar-Medical’s WatchPAT home test device for the diagnosis of obstructive sleep apnea.The Sleep Complete package will be offered to dentists through a bundled financing package which should significantly lower the financial barrier to entry that often faces dentists interested in incorporating sleep medicine into their practice. Read the rest of this entry

People with obstructive sleep apnea are more likely to stick to prescribed treatment when a partner or parent is involved with their treatment, according to a team of sleep researchers.

Obstructive sleep apnea occurs when the upper airway collapses during sleep. It is the most common type of sleep-disordered breathing, and chances of it occurring become more elevated in obese people.

The first line of treatment for sleep apnea is a non-invasive in-home treatment called CPAP, continuous positive airway pressure therapy. However, if patients do not use the equipment properly, or at all, it cannot help. Read the rest of this entry

NovaSom, Inc., the leader  in obstructive sleep apnea (OSA) home testing and cost-containment solutions, announces the launch of its next generation MediTrack(R) cloud-based CRM  application. The MediTrack OSA management platform is designed to enable custom  processing of payer-specific medical policy, billing, utilization management and  therapy coordination requirements to efficiently manage home sleep testing, OSA  diagnosis and recommended therapy.

NovaSom’s proprietary MediTrack system allows physicians to order a NovaSom  home sleep test online or by fax. The platform provides customizable information fields for easier physician entry of payer required data, leverages payer  communication preferences, and incorporates payer-specific messaging into patient shipping and handling and device return logistics. The system also manages rapid upload of patient sleep data for interpretation by a Board Certified physician, and then promptly publishes the OSA study results for secure online and fax delivery to the ordering physician. Upon positive diagnosis, the MediTrack technology integrates assignment of payer-preferred therapy providers. Read the rest of this entry

Gaylord Sleep Medicine now offers a full Sleep Apnea Management (SAM)  program at their Glastonbury, Guilford, North Haven and Trumbull locations.

Previously offering patient counseling and education services, the new Sleep  Apnea Management program has expanded to offer PAP (positive airway pressure)  equipment specifically suited to individual patient needs. Originally designed  to improve PAP compliance, the program continues to offer PAP therapy,  one-on-one counseling and follow-up care to maximize the patient’s early  treatment experience and comfort with the PAP device. Read the rest of this entry

St. Luke’s Sleep Medicine and Research Center is now enrolling participants in a clinical study to evaluate the safety and effectiveness of the Apnex Hypoglossal Nerve Stimulation (HGNS) System, an implantable device, to treat obstructive sleep apnea (OSA).

“Continuous positive airway pressure (CPAP), which involves a pressurized mask over the nose, is considered the ‘gold standard’ for the treatment of sleep apnea, but many people have difficulty tolerating it,” said Paula Schweitzer, PhD, St. Luke’s Sleep Medicine and Research Center director of research. “This implantable device offers a new approach for those who have not had success with CPAP or other sleep apnea treatments.”

People interested in learning if they qualify for the Apnex Clinical Study may call 888-975-3370 begin_of_the_skype_highlighting            888-975-3370     end_of_the_skype_highlighting or visit stlukes-stl.com/sleep. Qualified participants will receive the medical device and care free of charge.

Patients with mild to moderate obstructive sleep apnea (OSA), a condition in which the airway collapses and blocks breathing for 10 seconds or more, may consider adjustable oral appliances (OAs), devices that fit within the mouth to prevent upper airway collapse, as an effective first-line treatment, according to two studies conducted by sleep medicine specialists from Walter Reed National Military Medical Center (WRNMMC) in Bethesda, Md. 

The retrospective, peer-reviewed studies, published in the December 2011 issue of CHEST, the official journal of the American College of Chest Physicians, and in the current issue of the Journal of Clinical Sleep Medicine (JCSM), the official journal of the American Academy of Sleep Medicine, provide findings on OAs from the largest patient populations studied to date. The studies found that adjustable OAs are nearly as effective as continuous positive airway pressure (CPAP) treatment for patients with a mild form of OSA and are more effective than fixed oral appliances, particularly in patients with moderate to severe OSA. Read the rest of this entry